SCHEMBL24599231

SCHEMBL24599231

CCc1ccc(C(O)COc2ccc(CC3SC(=O)N(C)C3=O)cc2)nc1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPARG P37231 16/20 0.72
CYP3A4 P08684 1/20 0.46
RXRA P19793 1/20 0.46
MPC2 O95563 1/20 0.45
CYP2C8 P10632 1/20 0.45
CYP2C9 P11712 1/20 0.45
AURKA O14965 1/20 0.36
KDM4A O75164 1/20 0.35
USP2 O75604 1/20 0.35
POLB P06746 1/20 0.35
ALOX15 P16050 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
FFAR1 O14842 1/20 0.34
MCL1 Q07820 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19217761 0.89 PPARG (0.68) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL18541508 0.84 PPARG (1.00) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL2328758 0.84 PPARG (1.00) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL18541506 0.84 PPARG (1.00) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL23836844 0.84 PPARG (1.00) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL2328760 0.84 PPARG (1.00) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL2266225 0.84 PPARG (1.00) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL6928369 0.84 PPARG (1.00) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL6929811 0.84 PPARG (1.00) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL2327405 0.84 PPARG (1.00) PPARGCYP3A4RXRAMPC2CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220211682-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME DEUTERX, LLC 2022-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220211682-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SLC5A2, PPARD, DPP4 PPARG 10/4885CYP3A4 108/4885RXRA 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.